Specialty Generics and the Rise of Biosimilars
By 2026, the focus of generic pharmaceuticals has shifted from "plain-vanilla" oral tablets to Specialty Generics and Biosimilars.
Specialty Generics: These are complex versions of drugs that are harder to manufacture, such as injectables, inhalers, or transdermal patches. Because they require more advanced technology, they face less competition and maintain higher price points than standard pills.
Biosimilars: These are generic-like versions of Biologic drugs (medicines made from living cells). Unlike chemical generics, biosimilars are "highly similar" rather than identical due to the complexity of living organisms. In 2026, biosimilars are a primary driver of growth in the oncology and autoimmune sectors.
1 lượt xem